Zdrowie i gospodarka · 07/11/2011

FDA Extends Comment Period for De Novo Classification Guidance

The Food and Drug Administration (FDA) is extending the comment period for its draft guidance on the De Novo classification process until January 3, 2012, due to a discrepancy in the comment period between the notice and the guidance document.